Skip to content
CancerIndex

Publication

PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data.

Authors not recorded

Immunotherapy2017PMID 28472902stubpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-CIVIC-20260908-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (8)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 8

Curated evidence

Evidence citing this paper (1)

civicProvenance
Source
CIViC — Clinical Interpretation of Variants in Cancer
Dataset
CIViC evidence items
Version
civic-2026-09-08
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
expert curation
License
CC0 1.0
PMID
28472902
Run
ING-CIVIC-20260908-000001
Open at source CuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.
TherapyCancerTypeLevelDirection · significanceRating (1–5)StatusEvidenceSource
CD274 Expression1
Atezolizumab + Avelumab + Durvalumab + Nivolumab + PembrolizumabSubstitutesLung Non-Small Cell CarcinomaCURATED_BROADERPredictiveBSupports Sensitivity Response3accepted
EID4857

In this meta-analysis of 14 studies with 2857 patients, the immunotherapy response rate was higher among PD-L1-positive patients (RR: 2.19, 95% CI: 1.63-2.94). PD-L1 expression was also related to bet… (full text at CIViC)

PMID 28472902 · Aguiar et al., 2017 · Open in CIViC

civic